Faculty profile

Saima Hassan

Back to faculty

Chercheur régulierDepartment of SurgeryUniversité de Montréal

Saima Hassan

Chercheur régulier

Department of Surgery

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

This is a research or leadership role; ask the department whether it includes supervision.
24 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 FRQS), most recently in 2018.
Supervisor on 1 trainee award (1 CIHR), most recently in 2024.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,025

Citations

316

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Université de Montréal profile.

Cancer du sein métastase Cancer du sein triple-négatif Inhibiteurs de PARP

Latest papers

Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: A multicenter prospective study.
Journal of Clinical Oncology · 2026 · senior author
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.
Advances in therapy · 2026
Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy · 2026

All 50 publications

Latest funding

Dissecting tumor and microenvironment influences of PARPi response in BRCA-mutant and BRCA-wild type breast cancer patients
CIHR · 2024 · Supervisor
$210,000
Chercheurs-boursiers cliniciens
FRQS · 2018 · Principal investigator
$111,234
Établissement de jeunes chercheurs cliniciens
FRQS · 2018 · Principal investigator
$45,000

All 3 grants and awards

50 publications.

Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: A multicenter prospective study.

Natasha Caminsky, Mariya Yordanova, Lucas Sidéris, Jean-Francois Boileau, Julie Lemieux, Catalin Liviu Dragos Mihalcioiu, Sylvie Lévesque, Marie‐Claude Guertin, Erica Julie Patocskai, Rami Younan, André Robidoux, Saima Noor Hassan

Journal of Clinical Oncology2026Senior author

DOI: 10.1200/jco.2026.44.16_suppl.596

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Gambaro K, Rachedi K, Basik M, Batist G, Saad F, Hassan S, Mes-Masson AM, Boudreau D, Vincent F, St-Hilaire E, Mackay H, Abdelsalam M, Yip SM, Hanel R, Shokar S, Senhaji Mouhri Z, Badin M, Klein-Panneton K, Awan AA, Marques M

Advances in therapy2026

DOI: 10.1007/s12325-026-03545-z PMID: 41806276

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Viens M, Geoffroy K, Meuriot E, Buccilli A, Mullins-Dansereau V, Myre ML, Paradisis S, Bardoul A, Kalin EM, Saraiva BA, Valencia J, Leclerc Desaulniers K, Hoang HD, Hassan S, Bell JC, Vanderhyden B, Alain T, Roy DG, Cook DP, Bourgeois-Daigneault MC

Molecular therapy : the journal of the American Society of Gene Therapy2026Open Access

DOI: 10.1016/j.ymthe.2026.04.061 PMID: 42093158

Precision targeting of the SASP in cancer therapy.

Hassan S, Ferbeyre G

Nature aging2026First author

DOI: 10.1038/s43587-025-01052-4 PMID: 41634463

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.

Aloss K, Frederick MI, Hassan S

NPJ breast cancer2026Senior author

DOI: 10.1038/s41523-026-00963-8 PMID: 42140928

Abstract GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer

Charles E. Geyer, Gong Tang, Valentina Nekljudova, Priya Rastogi, Mattea Reinisch, Joshua Acosta, Andreas Schneeweiß, Christie J. Hilton, Sabine Seiler, Carsten Denkert, Rohit Bhargava, Patricia Cortazar, Fernando Moreno, Jay Andersen, Stephani Christensen, Peter Klare, Sujatha Murali, Serafin M. Morales, Jens Huober, Jean-François Boileau, Christian Jackisch, Álvaro Rodríguez-Lescure, Dominique K. Boudreau, Dirk-Michael Zahm, Claus Alexander Hanusch, Peter James Polewski, Kerstin Lüdtke-Heckenkamp, Saima Noor Hassan, João Mouta, Eleftherios P. Mamounas, et al. (32 authors)

Clinical Cancer Research202516 citations

DOI: 10.1158/1557-3265.sabcs24-gs3-05

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Aalto T, Abacan M, Abadi S, Aghababazadeh FA, Abbaszadeh Z, Abdelsalam M, Abdul Razak A, Abdulsalam S, Abelman DD, Abolghasemi A

Cancer Cell20256 citations

DOI: 10.1016/j.ccell.2025.03.014

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Frederick MI, Fyle E, Clouvel A, Abdesselam D, Hassan S

Translational oncology20254 citationsSenior authorOpen Access

DOI: 10.1016/j.tranon.2025.102337 PMID: 40054125

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Gambaro K, Rachedi K, Basik M, Saad F, Mes-Masson AM, Hassan S, Orimoto A, Boudreau D, Vincent F, St-Hilaire E, Mackay H, Abdelsalam M, Yip SM, Awan A, Hanel R, Guillemette S, Leite R, Caron MA, Patel C, Batist G, Marques M

Breast cancer : basic and clinical research20251 citationsOpen Access

DOI: 10.1177/11782234251395892 PMID: 41341273

Abstract 5722: Gene expression analysis of different PARPi combination approaches with carboplatin at primary tumor and metastatic site in xenograft model of triple-negative breast cancer

Djihane Abdesselam, Mallory I. Frederick, Saima Noor Hassan

Cancer Research2025Senior author

DOI: 10.1158/1538-7445.am2025-5722

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Saima Hassan

Research

Latest papers

Latest funding

Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: A multicenter prospective study.

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Precision targeting of the SASP in cancer therapy.

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.

Abstract GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Abstract 5722: Gene expression analysis of different PARPi combination approaches with carboplatin at primary tumor and metastatic site in xenograft model of triple-negative breast cancer

Dissecting tumor and microenvironment influences of PARPi response in BRCA-mutant and BRCA-wild type breast cancer patients

Chercheurs-boursiers cliniciens

Établissement de jeunes chercheurs cliniciens

Frequent collaborators

Mark Basik

Catalin Mihalcioiu

Anne-Marie Mes-Masson

Gerald Batist

Cagla Eskicioglu

Rebecca Gladdy

Patricia Tonin

May Quan

Francis Rodier

Shawn Forbes

Rossanna Pezo

Sylvie Lévesque

Ari Doumouras

Wilson Miller

Carol Swallow

Erin Kennedy

Frances Wright

Peter Siegel

Abha Gupta

Aisha Lofters

Fred Saad

Saima Hassan

Research

Latest papers

Latest funding

Application of a neoadjuvant 21-gene breast recurrence score assay to redirect surgical and systemic treatment pathways in early breast cancer: A multicenter prospective study.

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Estrogen-mediated NF-&#x3ba;B blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Precision targeting of the SASP in cancer therapy.

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights.

Abstract GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Abstract 5722: Gene expression analysis of different PARPi combination approaches with carboplatin at primary tumor and metastatic site in xenograft model of triple-negative breast cancer

Dissecting tumor and microenvironment influences of PARPi response in BRCA-mutant and BRCA-wild type breast cancer patients

Chercheurs-boursiers cliniciens

Établissement de jeunes chercheurs cliniciens

Frequent collaborators

Mark Basik

Catalin Mihalcioiu

Anne-Marie Mes-Masson

Gerald Batist

Cagla Eskicioglu

Rebecca Gladdy

Patricia Tonin

May Quan

Francis Rodier

Shawn Forbes

Rossanna Pezo

Sylvie Lévesque

Ari Doumouras

Wilson Miller

Carol Swallow

Erin Kennedy

Frances Wright

Peter Siegel

Abha Gupta

Aisha Lofters

Fred Saad

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.